Related Experiment Video

Updated: Mar 8, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Promoter Polymorphism of Toll-Like Receptor 4 is Associated with a Decreased Risk of Coronary Artery Disease: A

Dandan Sun1,2, Liping Sun1, Qian Xu1

  • 1Department of Tumor Etiology and Screening, Cancer Institute and General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China (mainland).

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|January 17, 2017
PubMed

Insights

This study found that a specific variation in the Toll-like receptor 4 (TLR4) gene promoter region, rs10116253, is associated with a reduced risk of coronary artery disease (CAD). This genetic factor may influence inflammatory pathways involved in CAD development.

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Immunology

Background:

  • Coronary artery disease (CAD) is a chronic inflammatory condition affecting blood vessels.
  • Toll-like receptor 4 (TLR4) plays a role in inflammatory responses.
  • Investigating genetic variations in TLR4 could reveal insights into CAD risk.

Purpose of the Study:

  • To investigate the association between polymorphisms in the promoter and 3'-untranslated regions (3'-UTR) of the TLR4 gene and the risk of developing CAD.
  • To identify specific TLR4 gene variants linked to altered CAD susceptibility.

Main Methods:

  • A case-control study involving 424 CAD patients and 424 healthy controls.
  • Genotyping of TLR4 polymorphisms (rs10116253, rs10983755, rs11536889) using polymerase chain reaction-restriction fragment length polymorphism.
  • Assessment of gene promoter activity using a dual-luciferase reporter assay.

Main Results:

  • The TLR4 rs10116253 polymorphism in the promoter region was significantly associated with CAD risk.
  • Carriers of variant genotypes (CC+TC) for rs10116253 showed a decreased risk of CAD (OR 0.73).
  • This reduced risk was particularly noted in males and individuals younger than 60 years old.

Conclusions:

  • The TLR4 rs10116253 polymorphism is linked to a reduced risk of coronary artery disease.
  • Genetic variations in TLR4 may modulate inflammatory processes contributing to CAD.
  • Further research into TLR4 genetics could inform CAD prevention strategies.

More Related Videos

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

24.9K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
77
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.2K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
789
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K